PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
- Conditions
- Healthy Subjects
- Interventions
- Drug: Placebo multiple doseDrug: Placebo single dose
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT02509117
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Inc, Glendale, California, United States
🇺🇸Glendale Adventist Medical Center, Glendale, California, United States
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: Etanercept
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 210
- Registration Number
- NCT02509026
- Locations
- 🇦🇺
Genesis Research Services Pty Ltd, Broadmeadow, New South Wales, Australia
🇦🇺Hunter Imaging Group, Cardiff, New South Wales, Australia
🇺🇸Winthrop University Hospital, Clinical Trials Center, Mineola, New York, United States
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
- Conditions
- Chronic Kidney Disease (CKD)
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 432
- Registration Number
- NCT02504294
- Locations
- 🇺🇸
Briggs Avenue Dialysis Center, Durham, North Carolina, United States
🇺🇸California Institute of Renal Research at Fresenius Medical Care Kearny Mesa, San Diego, California, United States
🇺🇸Nephrology Associates, PC, Nashville, Tennessee, United States
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT02501902
- Locations
- 🇺🇸
UC San Diego Medical Center - La Jolla (Thornton Hospital), La Jolla, California, United States
🇺🇸UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States
🇺🇸Anschutz Cancer Pavilion, Aurora, Colorado, United States
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
- Conditions
- Urinary Bladder, Neurogenic
- Interventions
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02501928
- Locations
- 🇯🇵
Fukuoka Children's Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵Osaka Women's and Children's Hospital, Izumi-shi, Osaka, Japan
Safety And Efficacy Of Bosutinib
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 702
- Registration Number
- NCT02501330
Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 97
- Registration Number
- NCT02497781
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇨🇿Lekarna Oblastni nemocnice Kolin, a.s., Kolin III, Czechia
🇺🇸ProMedica Toledo Children's Hospital, Toledo, Ohio, United States
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT02499146
- Locations
- 🇨🇳
The first hospital of jilin university, Changchun, Jilin, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Beijing Cancer Hospital/Oncology department, Beijing, Beijing, China
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 125
- Registration Number
- NCT02499120
- Locations
- 🇯🇵
Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
🇺🇸Henry Joyce Cancer Clinic, Nashville, Tennessee, United States
🇯🇵Aichi cancer center Central hospital, Nagoya, Aichi, Japan
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
- Conditions
- Staphylococcal Infections
- Interventions
- Biological: Staphylococcus aureus 4-antigen vaccineBiological: Placebo
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 136
- Registration Number
- NCT02492958
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital (formerly Medical Co. LTA Sumida Hospital), Sumida-ku, Tokyo, Japan
🇯🇵SOUSEIKAI PS Clinic (formerly Medical Co. LTA PS Clinic), Fukuoka, Japan